Adaptive vs Conventional Chronic Deep Brain Stimulation: Results from a Randomized Pilot Trial in Parkinson’s Disease
Objective: To assess the safety and efficacy of chronic adaptive (aDBS) and conventional (cDBS) deep brain stimulation of the subthalamic nucleus in patients with Parkinson’s…Efficacy of Novel A2A/A1 Antagonist in Motor and non-Motor Symptoms of MPTP-Treated Macaques
Objective: Our primary objective was to test the novel adenosine A2A/A1 receptor antagonist IDAA-338 in alleviating Parkinsonian symptoms when given as a mono or as…Investigation of the Quantitative Impact of T-type Calcium Channels in Subthalamic Nucleus Neurons on Parkinson’s Disease
Objective: Parkinson's disease (PD) might be seen as a classic manifestation of "brain arrhythmias" from a pathological standpoint. This work aims to examine the impact…Cohort study and Review on Physiotherapy in the Rehabilitation and Pro-longed Bed Rest of Atypical Parkinsonism’s Syndrome Patients
Objective: To present a cohort report on the physical decline and impact on activities of daily life (ADL) of prolonged bedrest for Atypical Parkinsonism's syndrome…First-In-Human Single and Multiple Ascending Dose Trial Design of LY3962681, a Novel Intrathecally Delivered siRNA Targeting α-synuclein mRNA for the Treatment of Patients with Parkinson’s Disease
Objective: Development of a Phase 1 clinical trial evaluating LY3962681, a novel, intrathecally delivered siRNA directly targeting α-synucleinmRNA (SNCA) to reduce α-synuclein protein (ASYN), for the treatment of…Boosting Clinical Trial Power in Parkinson’s Disease with AI-Generated Digital Twins
Objective: To evaluate the incorporation of prognostic digital twins to enhance traditional clinical trials in Parkinson’s Disease (PD) for disease modifying therapies. We assess the…Mortality Rate, Cause of Death and Factors Associated with Mortality in Late Stage Parkinson’s Disease
Objective: The aim was to carry out a long-term follow-up of a cohort of patients in late stage Parkinson’s disease (PD) with focus on mortality…Validating the clinical stage NLRP3 inflammasome inhibitor nibrozetone as a disease-modifying therapeutic for Parkinson’s disease
Objective: We recently confirmed that nibrozetone (RRx-001), a Phase 3 small molecule chemoprotective agent, is a direct NLRP3 inhibitor that is CNS permeable. Nibrozetone displays…Neuroprotective role of baicalein via autophagy mediated modulation of associated motor proteins in experimental animals of Parkinson disease
Objective: To evaluate neuroprotective role of baicalein via autophagy mediated modulation of associated motor proteins in rotenone induced mice model of Parkinson disease. Background: Parkinson's…Effect of various mGlu2 and mGlu2/3 activators on parkinsonism: a sub-analysis in the MPTP-lesioned primate
Objective: To evaluate the effect of the metabotropic glutamate 2/3 (mGlu2/3) orthosteric activators (OAs) LY-354,740 and LY-404,039, as well as the effects of the metabotropic…
- « Previous Page
- 1
- …
- 135
- 136
- 137
- 138
- 139
- …
- 1554
- Next Page »